

6 vs. 3 Cycles of epirubicin/docetaxel + G-CSF in operable breast cancer: Results of ABCSG-14.

Sub-category:

Adjuvant Therapy

Category:

Breast Cancer - Local-Regional and Adjuvant Therapy

Meeting:

2004 ASCO Annual Meeting

Session Type and Session Title:

Poster Discussion Session, Breast Cancer I

Abstract No:

553

Citation:

Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol : Supplement), 2004: 553

Author(s):

G. G. Steger, E. Kubista, H. Hausmaninger, M. Gnant, C. Tausch, A. Lang, H. Samonigg, A. Galid, Austrian Breast and Colorectal Cancer Study Group; Medical University of Vienna, Vienna, Austria; Salzburg, Austria; Barmherzige Schwestern, Linz, Austria; Feldkirch Hospital, Feldkirch, Austria; Me Graz, Graz, Austria

Abstract:

Background: Preoperative chemotherapy (PROP) for operable breast cancer is established to do primarily not suitable for breast conserving surgery. A pathologic complete response (pCR) after PR surrogate marker for longer overall survival (OS) but the rates of pCR with current treatment regime and a beneficial effect of PROP upon OS remains to be established. In 1999, the ABCSG set out to whether prolonging the time of the neoadjuvant treatment period by doubling the number of cycles might raise the rate of pCR after PROP by converting more partial responses into pCR's. **Methods:** biopsy proven breast cancer T1-4_{a-c},N+/-,M0 were eligible for this prospectively randomized phase I (estimated drop-out rate: 5%) were planned to detect a significant difference (one-sided p < 0,05, Fi a power of 82%. Pts were randomized to receive either 3 cycles of epirubicin 75mg/m² and docetaxi G-CSF 30 MU days 3-10 q 21 days (ED+G) or 6 cycles of the identical regimen. Primary end point v The pathological nodal status and the rate of breast conserving surgical procedures served as seco **Results:** 292 pts were accrued to the trial between 6/199 and 12/2002 and 288 pts are eligible. Botl well balanced for tumor size, clinical nodal status, menopausal status, hormone receptor status, HE center. The results of the primary and the secondary end points are depicted in the table. There was difference in serious adverse events per patient and per cycle and no patient died while on treatmer

Results of 3 vs. 6 cycles of neoadjuvant ED+G in operable Breast Cancer		
	3 x ED+G (n=143)	6 x ED+G (n=144)
pathological Complete Response	11 (7,7%)	27 (18,6%)
Negative nodal status	59 (42,8%)	77 (56,6%)
Breast conserving surgery	93 (66,9%)	104 (75,9%)

Conclusions: Doubling the number of cycles of neoadjuvant chemotherapy (6 vs. 3 x ED+G) resu higher rates for pCR and negative axillary nodal status with with no excess of side effects.

► **Associated Presentation(s):**

1. 6 vs. 3 Cycles of epirubicin/docetaxel + G-CSF in operable breast cancer: Results of ABCSG-14.

Meeting: [2004 ASCO Annual Meeting](#)

Presenter: [Guenther G. Steger](#)

Session: [Breast Cancer I \(Poster Discussion Session\)](#)

► **Other Abstracts in this Sub-Category:**

1. Prediction of the therapeutic response to paclitaxel by gene expression profiling in neoadjuvant chemotherapy for breast cancer.

Meeting: [2004 ASCO Annual Meeting](#) Abstract No: 500 First Author: [M. Yoshimoto](#)

Category: [Breast Cancer - Local-Regional and Adjuvant Therapy - Adjuvant Therapy](#)

2. Changes in gene expression profiling due to primary chemotherapy in patients with locally advanced breast cancer.

Meeting: [2004 ASCO Annual Meeting](#) Abstract No: 502 First Author: [J. Hannemann](#)

Category: [Breast Cancer - Local-Regional and Adjuvant Therapy - Adjuvant Therapy](#)

3. The effect of CYP 2D6 genotype and CYP2D6 inhibitors on tamoxifen.

Meeting: [2004 ASCO Annual Meeting](#) Abstract No: 508 First Author: [V. Stearns](#)

Category: [Breast Cancer - Local-Regional and Adjuvant Therapy - Adjuvant Therapy](#)

[More...](#)

► **Abstracts by G. G. Steger:**

1. Brain metastasis-free survival in patients with HER2-positive metastatic breast cancer.

Meeting: [2011 Breast Cancer Symposium](#) Abstract No: 41 First Author: [A. Berghoff](#)

Category: [Detection, Screening, and Imaging - Predictive and Prognostic Factors](#)

2. Effect of change of body mass index (BMI) during therapy on the efficacy of endocrine therapy in premenopausal patients with breast cancer: An analysis of the ABCSG-12 trial.

Meeting: [2011 ASCO Annual Meeting](#) Abstract No: 514 First Author: [G. Pfeiler](#)

Category: [Breast Cancer - HER2/ER - ER+](#)

3. Impact of HER2-targeted therapy on overall survival (OS) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC).

Meeting: [2011 ASCO Annual Meeting](#) Abstract No: 572 First Author: [A. Berghoff](#)

Category: [Breast Cancer - HER2/ER - HER2+](#)

[More...](#)

► **Presentations by G. G. Steger:**

1. Pathologic complete response (pCR) in patient subgroups: An analysis of ABCSG-24, a phase III, randomized study of anthracycline- and taxane-based neoadjuvant therapy with or without capecitabine in early breast cancer (EBC).

Meeting: [2010 ASCO Annual Meeting](#)

Presenter: [Guenther G. Steger](#)

Session: [Breast Cancer - Local-Regional and Adjuvant Therapy](#) (Poster Discussion Session)

2. 6 vs. 3 Cycles of epirubicin/docetaxel + G-CSF in operable breast cancer: Results of ABCSG-14.

Meeting: [2004 ASCO Annual Meeting](#)

Presenter: [Guenther G. Steger, MD](#)

Session: [Breast Cancer I](#) (Poster Discussion Session)

3. Fulvestrant beyond the second hormonal treatment line in metastatic breast cancer

Meeting: [2003 ASCO Annual Meeting](#)

Presenter: [Gunther G Steger, MD](#)

Session: [Late Breast Cancer](#) (Poster Discussion Session)

[More...](#)

► ***Educational Book Manuscripts by G. G. Steger:***

No items found.